Fig. 1.

ZA exerts antitumor activity in TSC2-null cell subcutaneous tumor model and LAM mouse model. a Tumor growth in STOCK-Foxn1nu/Nju female athymic nude mice with TSC2-null cells given by 1 mg/kg/3 day zoledronic acid (ZA) through the tail vein (n = 6). b Body weights of nude mice with TSC2-null cell tumors were subjected to 30-d treatment with placebo and ZA, respectively (n = 6). c Immunofluorescence of Ki67 in the subcutaneous mice model. Scar bar, 100 μm (n = 6). d Tumor lesion sections stained for p-S6 (ser 234/235) (n = 6). Scar bar, 50 μm. e H&E staining of lung lesions of placebo- and ZA-injected mice after tail vein injection of TSC2-null cells for 30 day (n = 6). Scar bar, 500 μm. The experiment was performed for three times. All data were presented as mean ± SEM. Compared with the placebo, ** P < 0.01, *** P < 0.001